Overview
- Abbott, which reported results Thursday, posted adjusted EPS of $1.15 in line with forecasts and revenue of $11.16 billion that topped estimates.
- Guidance now calls for full‑year adjusted EPS of $5.38 to $5.58, with about $0.20 per share of dilution tied to the March Exact Sciences deal and Q2 EPS of $1.25 to $1.31.
- The Exact Sciences acquisition adds a cancer diagnostics platform that Abbott expects to contribute about $3 billion of 2026 sales under its new comparable sales reporting.
- Profitability tightened as the adjusted operating margin fell to roughly 12% from about 16.3% a year earlier, reflecting higher costs and acquisition‑related items.
- Shares fell roughly 4%–6% to a new 52‑week low after the release, as investors weighed near‑term margin pressure against strong device growth and a planned second‑half acceleration.